By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Enanta Pharmaceuticals, Inc. 

500 Arsenal Street

Watertown  Massachusetts  02472  U.S.A.
Phone: 617-607-0800 Fax: 617-607-0530


SEARCH JOBS


Industry
Pharmaceutical






Company News
Enanta Pharmaceuticals, Inc. To Host Conference Call On August 8 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2016 7/18/2016 9:56:39 AM
Enanta Pharmaceuticals, Inc. Initiates Proof-Of-Concept Study With Pan-Genotypic Cyclophilin Inhibitor EDP-494 In Patients With Genotype 1 Or Genotype 3 Chronic Hepatitis C Virus 6/20/2016 10:44:03 AM
Enanta Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences 6/2/2016 9:58:06 AM
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2016 5/10/2016 11:57:40 AM
Enanta Pharmaceuticals, Inc. To Host Conference Call On May 9 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Second Quarter Ended March 31, 2016 4/28/2016 10:21:45 AM
Enanta Pharmaceuticals, Inc. To Present At The Deutsche Bank (DB) 41st Annual Healthcare Conference Presentation To Be Webcast On May 4, 2016 At 8:00 A.M. ET 4/26/2016 12:09:39 PM
Enanta Pharmaceuticals, Inc. Announces FDA Has Approved AbbVie (ABBV)’s Supplemental New Drug Application For Use Of VIEKIRA PAK Without Ribavirin In Genotype 1b Chronic Hepatitis C Patients With Compensated Cirrhosis 4/25/2016 8:34:19 AM
Enanta Pharmaceuticals, Inc. Announces New Data From AbbVie (ABBV)’s SURVEYOR-1 And SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates After 8 Or 12 Weeks Of Treatment In Patients With Any Of Genotypes 1 Through 6 Of Hepatitis C Virus 4/18/2016 11:15:20 AM
Enanta Pharmaceuticals, Inc. Announces High SVR Rates With AbbVie (ABBV)’s VIEKIRAX + EXVIERA Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients 4/15/2016 10:01:11 AM
Enanta Pharmaceuticals, Inc. Announces That AbbVie (ABBV)’s Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals 4/15/2016 9:48:56 AM
12345678910...
//-->